Therefore, it is reported in vitro and for the first time, that the significantly downregulatory activity exerted by nintedanib on the tyrosine kinase receptor MerTK expression might represent one of the major therapeutic effects linked to the ILD clinical improvement observed in treated SSc patients. The gene discussed is NTRK1; the disease is systemic sclerosis.